• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23574 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     NIHR Health and Social Care Delivery Program Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: medical imaging of the head]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to managing people with colorectal cancer]
2024     NIHR Health Services and Delivery Research programme Strengthening open disclosure in maternity services in the English NHS: the DISCERN realist evaluation study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: quantification of antipsychotics in serum using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – addendum to project H23-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – assessment according to §137h Social Code Book (SGB) V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefepime/enmetazobactam (bacterial infections, several therapeutic indications) – Addendum to Project G24-15]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – addendum to Project A24-66]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (follicular lymphoma) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crovalimab (paroxysmal nocturnal haemoglobinuria) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – addendum to Project A24-46]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 2 diabetes mellitus) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 1 diabetes mellitus) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (maintenance in combination with durvalumab; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (ulcerative colitis) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – benefit assessment according to §35a Social Code Book (SGB) V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours with a neurotrophic tyrosine receptor kinase [NTRK] gene fusion, > 1 month to < 12 years) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - marstacimab (haemophilia A and B)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for onasemnogene-abeparvovec (spinal muscular atrophy): Review of the study protocol (Version 4.01) and statistical analysis plan (Version 4.0) – fourth addendum to project A20-61]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheter exchange prior to sample collection 2024 update
2024     HTA South [Intrathecal treatment of cancer pain]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: gradual return to activities following a mild traumatic brain injury or concussion (MTBI/concussion)]
2024     NIHR Health Services and Delivery Research programme Interpersonal counselling for adolescent depression delivered by youth mental health workers without core professional training: the ICALM feasibility RCT
2024     NIHR Health Technology Assessment programme Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling
2024     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis
2024     NIHR Health and Social Care Delivery Program Exploratory study from an end-of-life research partnership network to improve access for ethnically diverse communities in one region
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacokinetics, efficacy and safety of and persistence with treatment with the generic versions of Concerta compared to Concerta]
2024     WorkSafeBC Rest as treatment for adhesive capsulitis: 2024 update
2024     WorkSafeBC Causal association between sprain/strain and myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia
2024     WorkSafeBC Noise-cancelling headphones as treatment for PTSD - 2024 update
2024     WorkSafeBC Association between complex regional pain syndrome, ketamine use, lower urinary tract symptoms and erectile dysfunction
2024     WorkSafeBC Efficacy/effectiveness of nSTRIDE injection in treating patients with knee osteoarthritis
2024     WorkSafeBC Efficacy/effectiveness of axillary nerve block to treat shoulder pain
2024     WorkSafeBC Effectiveness of prolotherapy in rotator cuff tendinopathy
2024     WorkSafeBC COVID-19 and perimyocarditis
2024     WorkSafeBC Effectiveness of botulinum toxin (botox), A or B, in treating painful neuroma: 2024 update
2024     WorkSafeBC Low intensity ultrasound for treating fracture nonunion and short reviews on other bone growth stimulator devices and orthobionomics: second update January 2024
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: psychosocial interventions in youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2024     NIHR Health Technology Assessment programme Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
2024     NIHR Health and Social Care Delivery Program Early mental health intervention and supported self-care for LGBTQ+ young people in the UK: a mixed-methods study
2024     NIHR Health Technology Assessment programme Collagenase injection versus limited fasciectomy surgery to treat Dupuytren’s contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: environmental impacts in health and social services - what role should health technology assessment agencies play?]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [The utility of neuropsychological tests for the detection and diagnosis of frontotemporal dementia (FTD)]
2024     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. NICE interventional procedures guidance 794
2024     National Institute for Health and Care Excellence (NICE) Digital technologies for assessing attention deficit hyperactivity disorder (ADHD). NICE diagnostics guidance 60
2024     National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024     National Institute for Health and Care Excellence (NICE) Belzutifan for treating tumours associated with von Hippel-Lindau disease. NICE technology appraisal guidance 1011
2024     National Institute for Health and Care Excellence (NICE) Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia. NICE technology appraisal guidance 1013
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: adjustment of antidepressants for the follow-up of a major depressive disorder or an anxiety disorder]
2024     Haute Autorite de sante (HAS) [Management missing teeth with implant-supported prostheses (complete edentulism or single missing teeth)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of placental growth factor (PlGF) testing in suspected preeclampsia]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: support for the implementation of a pilot project on the targeted use of medications for the treatment of obesity in designated centers]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evaluation of the lung cancer screening pilot project - effects on participants' health and organizational impact on the healthcare system]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Vosoritide in achondroplasia]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Partially hydrolyzed formula to prevent cow’s milk allergy]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: access to innovations in health and social services - financing and decision-making]
2024     NIHR Health Technology Assessment programme Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024     Norwegian Medical Products Agency (NOMA) [Interferon gamma-1b for treatment of Friedreich’s ataxia: a health technology assessment without submitted documentation]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: prolotherapy's efficacy and safety in the treatment of chronic musculoskeletal pain]
2024     Health Sciences Institute in Aragon (IACS) [Portable external trigeminal nerve stimulator (eTNS) device for the treatment of migraine headaches]
2024     NIHR Health and Social Care Delivery Program The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2024     NIHR Health and Social Care Delivery Program Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024     NIHR Health and Social Care Delivery Program Understanding and improving the quality of primary care for people in prison: a mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood quantification of fludarabine by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)]
2024     Norwegian Institute of Public Health (NIPH) [Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2024     NIHR Health and Social Care Delivery Program Pathways to specialist community perinatal mental health services: a two-site longitudinal retrospective service evaluation
2024     NIHR Health and Social Care Delivery Program What happens between first symptoms and first acute exacerbation of COPD – observational study of routine data and patient survey
2024     NIHR Health Services and Delivery Research programme Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     NIHR Health and Social Care Delivery Program Using the Recommended Summary Plan for Emergency Care and Treatment in Primary Care: a mixed methods study
2024     NIHR Health and Social Care Delivery Program Implementing an artificial intelligence command centre in the NHS: a mixed-methods study
2024     NIHR Health Technology Assessment programme Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis
2024     NIHR Health Technology Assessment programme Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT
2024     NIHR Health Technology Assessment programme Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     NIHR Health Technology Assessment programme Behavioural interventions to treat anxiety in adults with autism and moderate to severe intellectual disabilities: the BEAMS-ID feasibility study
2024     NIHR Health Technology Assessment programme Timing of Stoma Closure in Neonates: the ToSCiN mixed-methods study
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Technology Assessment programme Interventions for people with perceptual disorders after stroke: the PIONEER scoping review, Cochrane systematic review and priority setting project
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: gene panel for the identification of inborn errors of immunity - evaluation report on the repatriation of an analysis carried out outside of the province of Québec]